Jeremy Mazurek, MD
Advanced Heart Failure and Transplant Cardiology · Philadelphia, PANPI 1336440254
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 43.8% of the total. 2025 is the largest year on record at $79,196, 9.9 times the $7,960 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $412.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$62K
- Merck$34K
- United Therapeutics Corporation$33K
- Abbott$5K
- Janssen Scientific Affairs, LLC$5K
- Cvrx, Inc.$1K
- plus $2K from 15 others
Across 10 payments — averaging $22,838 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$174K
- Actelion Pharmaceuticals, Ltd$33K
- United Therapeutics Corporation$22K
What the payments were for
- Consulting fees$64,75846%
- Speaking & faculty fees$51,31136%
- Travel & lodging$13,99110%
- Food & beverage$11,9548%
- Education$1630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 102 | $62,322 |
| Merck | 38 | $34,332 |
| United Therapeutics Corporation | 96 | $33,079 |
| Abbott | 35 | $4,994 |
| Janssen Scientific Affairs, LLC | 7 | $4,500 |
| Cvrx, Inc. | 11 | $1,003 |
| Medtronic(2 entities) | 8 | $475 |
| AstraZeneca | 15 | $318 |
| Abiomed | 3 | $311 |
| Alnylam Pharmaceuticals Inc. | 7 | $200 |
| Bayer | 5 | $169 |
| Gilead | 5 | $160 |
| Edwards Lifesciences | 2 | $84 |
| Esperion Therapeutics, Inc. | 2 | $49 |
| Novo Nordisk | 2 | $44 |
| Bridgebio Pharma, Inc. | 2 | $38 |
| Impulse Dynamics (USA) Inc. | 1 | $32 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Novartis | 1 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| Sensible Medical Innovations Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$51,557
- OPSUMIT$43,086
- WINREVAIR$17,759
- ORENITRAM$8,011
- HeartMate$2,025
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,981
- TYVASO$716
- REMODULIN$716
- Barostim Neo System$661
- HeartWare HVAD$334
- CARDIOMEMS$314
- Impella$284
- AMVUTTRA$147
How this compares
$142,177 in reported general payments places this provider in the 90th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
See all advanced heart failure and transplant cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 111 | $1,554,776 |
| AdempasRiociguat | 98 | $1,383,394 |
| UptraviSelexipag | 32 | $874,405 |
| Tyvaso DpiTreprostinil | 34 | $835,511 |
| WinrevairSotatercept-Csrk | 22 | $306,649 |
| RemodulinTreprostinil Sodium | 19 | $223,145 |
| Ambrisentan | 33 | $108,311 |
| EntrestoSacubitril/Valsartan | 92 | $86,528 |
| JardianceEmpagliflozin | 74 | $76,963 |
| EliquisApixaban | 49 | $63,703 |
| Sildenafil Citrate | 97 | $37,213 |
| Tadalafil | 28 | $34,501 |
| FarxigaDapagliflozin Propanediol | 37 | $25,754 |
| Bumetanide | 45 | $3,158 |
| Potassium Chloride | 49 | $2,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $62,322 | $2,429,181143 claims |
| BayerAdempas | $169 | $1,383,39498 claims |
| MerckWinrevair | $34,332 | $306,64922 claims |
| United Therapeutics CorporationRemodulin | $33,079 | $223,14519 claims |
| NovartisEntresto | $20 | $86,52892 claims |
| Boehringer IngelheimJardiance | $17 | $76,96374 claims |
| AstraZenecaFarxiga | $318 | $25,75437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
Other advanced heart failure and transplant cardiology in Philadelphia
- Anjali VaidyaPhiladelphia$762K
- Jesus RamePhiladelphia$336K
- Ileana PinaPhiladelphia$284K
- Lee GoldbergPhiladelphia$130K
- Anjali OwensPhiladelphia$109K
- Behnam BozorgniaPhiladelphia$107K
- Joyce WaldPhiladelphia$97K
- Paul MatherPhiladelphia$55K
- Hansie MathelierPhiladelphia$43K
- Nosheen RezaPhiladelphia$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.